EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cardiovascular Disease in Diabetes and Chronic Kidney Disease

Sowmya Swamy, Sahibzadi Mahrukh Noor, Roy O Mathew iD

Journal of Clinical Medicine · 08.11.2023 · 12 (22) · 6984

DOI: 10.3390/jcm12226984 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 08.11.2023. Verfasst von Sowmya Swamy und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, School of Medicine, George Washington University, Washington, DC 20052, USA. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease (CKD) is a common occurrence in patients with diabetes mellitus (DM), occurring in approximately 40% of cases. DM is also an important risk factor for cardiovascular disease (CVD), but CKD is an important mediator of this risk. Multiple CVD outcomes trials have revealed a greater risk for CVD events in patients with diabetes with CKD versus those without. Thus, reducing the risk of CKD in diabetes should result in improved CVD outcomes. To date, of blood pressure (BP) control, glycemic control, and inhibition of the renin-angiotensin system (RASI), glycemic control appears to have the best evidence for preventing CKD development. In established CKD, especially with albuminuria, RASI slows the progression of CKD. More recently, sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide receptor agonists (GLP1RA) have revolutionized the care of patients with diabetes with and without CKD. SGLT2i and GLP1RA have proven to reduce mortality, heart failure (HF) hospitalizations, and worsening CKD in patients with diabetes with and without existing CKD. The future of limiting CVD in diabetes and CKD is promising, and more evidence is forthcoming regarding combinations of evidence-based therapies to further minimize CVD events.

Schlagwörter

Stichwörter der Autor:innen

cardiovascular diseasechronic kidney diseasediabetes mellitusepidemiologysglt2 inhibitors

Autor:innen und Institutionen

  • Department of Medicine, School of Medicine, George Washington University, Washington, DC 20052, USA.
  • Department of Medicine, School of Medicine, Loma Linda University, Loma Linda, CA 92350, USA.
  • Department of Medicine, Loma Linda VA Healthcare System, 11201 Benton Street, Loma Linda, CA 92357, USA.

ORCID-Profile: Roy O Mathew

Zitieren

APA

Swamy, S., Noor, S. M., & Mathew, R. O. (2023). Cardiovascular Disease in Diabetes and Chronic Kidney Disease. Journal of Clinical Medicine, 12(22), 6984. https://doi.org/10.3390/jcm12226984

Vancouver

Swamy S, Noor SM, Mathew RO. Cardiovascular Disease in Diabetes and Chronic Kidney Disease. Journal of Clinical Medicine. 2023;12(22):6984. doi:10.3390/jcm12226984

BibTeX
@article{Swamy2023,
  author = {Swamy, Sowmya and Noor, Sahibzadi Mahrukh and Mathew, Roy O},
  title = {Cardiovascular Disease in Diabetes and Chronic Kidney Disease},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {22},
  pages = {6984},
  doi = {10.3390/jcm12226984}
}
Kostenlos starten →